Answers are grounded in this paper and cite their sources.
Although there are various treatment modalities available for hepatocellular carcinoma (HCC), HCC is still among the most common causes of cancer-related death globally. Identifying independent biomarkers of poor prognosis in HCC patients remains a critical goal to allow timely intervention and ameliorate patient survival. MicroRNAs (miRNAs), the most widely investigated small noncoding RNAs to date, play a crucial role in regulating the initiation and progression of HCC. The expression of numerous miRNAs is altered in tumor tissues and blood specimens of HCC patients, underscoring their potential as promising prognostic biomarkers. This review offers an exhaustive overview of the current literature examining tissue- and circulation-derived miRNAs as single or combined independent prognostic biomarkers in HCC patients.
No takes yet. Share an insight, caveat, or question.
Ll et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: